These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26415829)

  • 21. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery.
    Sakuma S; Suita M; Inoue S; Marui Y; Nishida K; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Uto T; Baba M
    Mol Pharm; 2012 Oct; 9(10):2933-41. PubMed ID: 22953762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
    Pawar D; Mangal S; Goswami R; Jaganathan KS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of chitosan microspheres for nasal delivery of vaccines.
    Kang ML; Cho CS; Yoo HS
    Biotechnol Adv; 2009; 27(6):857-865. PubMed ID: 19583998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae.
    Goetsch L; Gonzalez A; Plotnicky-Gilquin H; Haeuw JF; Aubry JP; Beck A; Bonnefoy JY; Corvaïa N
    Infect Immun; 2001 Oct; 69(10):6434-44. PubMed ID: 11553588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation and evaluation of antigen/N-trimethylaminoethylmethacrylate chitosan conjugates for nasal immunization.
    Liu Q; Zhang C; Zheng X; Shao X; Zhang X; Zhang Q; Jiang X
    Vaccine; 2014 May; 32(22):2582-90. PubMed ID: 24681230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal immunization with poly(γ-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity.
    Matsuo K; Koizumi H; Akashi M; Nakagawa S; Fujita T; Yamamoto A; Okada N
    J Control Release; 2011 Jun; 152(2):310-6. PubMed ID: 21402114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoglobulin immobilized liposomal constructs for transmucosal vaccination through nasal route.
    Tiwari B; Agarwal A; Kharya AK; Lariya N; Saraogi G; Agrawal H; Agrawal GP
    J Liposome Res; 2011 Sep; 21(3):181-93. PubMed ID: 20626315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations.
    Christensen D; Foged C; Rosenkrands I; Lundberg CV; Andersen P; Agger EM; Nielsen HM
    Int J Pharm; 2010 May; 390(1):19-24. PubMed ID: 19879346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conjugating influenza a (H1N1) antigen to n-trimethylaminoethylmethacrylate chitosan nanoparticles improves the immunogenicity of the antigen after nasal administration.
    Liu Q; Zheng X; Zhang C; Shao X; Zhang X; Zhang Q; Jiang X
    J Med Virol; 2015 Nov; 87(11):1807-15. PubMed ID: 25959372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization.
    Wu Y; Wei W; Zhou M; Wang Y; Wu J; Ma G; Su Z
    Biomaterials; 2012 Mar; 33(7):2351-60. PubMed ID: 22192540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel antigen-carrier system: the Mycobacterium tuberculosis Acr protein carried by raw starch microparticles.
    Moreno-Mendieta SA; Guillén D; Espitia C; Hernández-Pando R; Sanchez S; Rodríguez-Sanoja R
    Int J Pharm; 2014 Oct; 474(1-2):241-8. PubMed ID: 25093695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fimbriae and recombinant cholera toxin B subunit.
    Takahashi Y; Kumada H; Hamada N; Haishima Y; Ozono S; Isaka M; Yasuda Y; Tochikubo K; Umemoto T
    Oral Microbiol Immunol; 2007 Dec; 22(6):374-80. PubMed ID: 17949339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal immunization against influenza virus using polymeric particles.
    Lemoine D; Deschuyteneer M; Hogge F; Préat V
    J Biomater Sci Polym Ed; 1999; 10(8):805-25. PubMed ID: 10487316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential of Translationally Controlled Tumor Protein-Derived Protein Transduction Domains as Antigen Carriers for Nasal Vaccine Delivery.
    Bae HD; Lee J; Jin XH; Lee K
    Mol Pharm; 2016 Sep; 13(9):3196-205. PubMed ID: 27454469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucosal immunity of nasopharynx: an experimental study in TCR-transgenic (OVA23-3) mice.
    Yamada T; Kataoka S; Ogasawara K; Ishimitsu R; Hashigucci K; Suzuki T; Kawauchi H
    Rhinology; 2005 Sep; 43(3):190-8. PubMed ID: 16218512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted delivery of mannan-coated superparamagnetic iron oxide nanoparticles to antigen-presenting cells for magnetic resonance-based diagnosis of metastatic lymph nodes in vivo.
    Vu-Quang H; Yoo MK; Jeong HJ; Lee HJ; Muthiah M; Rhee JH; Lee JH; Cho CS; Jeong YY; Park IK
    Acta Biomater; 2011 Nov; 7(11):3935-45. PubMed ID: 21763797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multifunctional liposomes constituting microneedles induced robust systemic and mucosal immunoresponses against the loaded antigens via oral mucosal vaccination.
    Zhen Y; Wang N; Gao Z; Ma X; Wei B; Deng Y; Wang T
    Vaccine; 2015 Aug; 33(35):4330-40. PubMed ID: 25858854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
    Tafaghodi M; Sajadi Tabassi SA; Jaafari MR
    Int J Pharm; 2006 Aug; 319(1-2):37-43. PubMed ID: 16701972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pluronic F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin.
    Kang ML; Jiang HL; Kang SG; Guo DD; Lee DY; Cho CS; Yoo HS
    Vaccine; 2007 Jun; 25(23):4602-10. PubMed ID: 17485148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety of a mucosal vaccine using the C-terminal fragment of Clostridium perfringens enterotoxin.
    Suzuki H; Kakutani H; Kondoh M; Watari A; Yagi K
    Pharmazie; 2010 Oct; 65(10):766-9. PubMed ID: 21105580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.